Since IL-3 is an early response cytokine transiently expressed at the early stage of T-cell activation and its aberrant expression has been linked to different leukemias [59], understanding how HuR protein regulates IL-3 mRNA expression at the post-transcriptional/translational level in T lymphocytes will be critical for developing effective therapies against cancer and other human blood disorders. This evidence concerns the gene ELAVL1 and leukemia.